Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
NCT ID: NCT05019716
Last Updated: 2025-12-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
36 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-07-13
Study Completion Date
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with cisplatin and etoposide or carboplatin and paclitaxel in treating patients with NUT carcinoma. Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certain growth-promoting proteins and may prevent proliferation of tumor cells that use those proteins for their growth. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Combination therapy with ZEN003694 and etoposide and cisplatin or carboplatin and paclitaxel may be safe and effective in treating patients with NUT carcinoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVE:
I. Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of the addition of BET bromodomain inhibitor ZEN-3694 (ZEN003694) to etoposide and cisplatin (EP) in participants with NUT carcinoma (NC).
SECONDARY OBJECTIVES:
I. Evaluate the preliminary progression-free survival (PFS) rate, overall response rate (ORR), duration of response (DoR), and overall survival (OS) of the addition of ZEN003694 to etoposide and cisplatin (EP) in participants with NC utilizing Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
II. Determine the pharmacokinetic (PK) profile of ZEN003694, etoposide, and cisplatin when administered in combination.
III. To observe and record anti-tumor activity. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) IV. Explore potential biomarker indicators of response and resistance in tumor tissue samples. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort)
V. To perform molecular profiling assays on malignant and normal tissues, including, but not limited to, whole exome sequencing (WES) and messenger ribonucleic acid (RNA) sequencing (RNAseq), in order to:
Va. Identify potential predictive and prognostic biomarkers beyond any genomic alteration by which treatment may be assigned; (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) Vb. Identify resistance mechanisms using genomic DNA- and RNA-based assessment platforms; (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) VI. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) VII. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the National Cancer Institute (NCI) Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) at Nationwide Children's Hospital. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) VIII. Evaluate the safety and tolerability of ZEN003694 in combination with carboplatin and paclitaxel in participants with NC. (ZEN003694/carboplatin/paclitaxel safety cohort) IX. To determine the PK profile of the combination of ZEN003694, carboplatin, and paclitaxel in combination. (ZEN003694/carboplatin/paclitaxel safety cohort)
OUTLINE: This is a dose escalation study of ZEN003694 with fixed dose etoposide and cisplatin OR fixed dose carboplatin and paclitaxel. Patients are assigned to 1 of 3 cohorts.
COHORT I (PHASE 1): Patients receive ZEN003694 orally (PO) once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive etoposide intravenously (IV) over 60 minutes on days 1-3 of each cycle and cisplatin IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then receive etoposide and cisplatin for an additional 4 cycles in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. After completion of etoposide and cisplatin treatment, patients may then receive ZEN003694 PO once or twice daily on days 1-14 or 1-21 of each cycle, per the treating investigator's discretion. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
COHORT II (SAFETY COHORT): Patients receive ZEN003694 PO once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive carboplatin IV over 15-30 minutes on day 1 of each cycle and paclitaxel IV over 3 hours on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then receive carboplatin and paclitaxel for an additional 4 cycles in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. After completion of carboplatin and paclitaxel treatment, patients may then receive ZEN003694 PO once or twice daily on days 1-14 or 1-21 of each cycle, per the treating investigator's discretion. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
COHORT III (NON-THORACIC, NON-BRD4 EXPLORATORY COHORT): Patients receive ZEN003694 PO on days 1-5, 8-12, and 15-19 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression have the option to cross-over to Cohort I and receive treatment for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Cross-over patients may then receive ZEN003694 PO on days 1-21 of each cycle in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
After completion of study treatment, patients are followed for 30 days after the last dose and then every 4 weeks for a maximum of 2 years.
I. Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of the addition of BET bromodomain inhibitor ZEN-3694 (ZEN003694) to etoposide and cisplatin (EP) in participants with NUT carcinoma (NC).
SECONDARY OBJECTIVES:
I. Evaluate the preliminary progression-free survival (PFS) rate, overall response rate (ORR), duration of response (DoR), and overall survival (OS) of the addition of ZEN003694 to etoposide and cisplatin (EP) in participants with NC utilizing Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
II. Determine the pharmacokinetic (PK) profile of ZEN003694, etoposide, and cisplatin when administered in combination.
III. To observe and record anti-tumor activity. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) IV. Explore potential biomarker indicators of response and resistance in tumor tissue samples. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort)
V. To perform molecular profiling assays on malignant and normal tissues, including, but not limited to, whole exome sequencing (WES) and messenger ribonucleic acid (RNA) sequencing (RNAseq), in order to:
Va. Identify potential predictive and prognostic biomarkers beyond any genomic alteration by which treatment may be assigned; (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) Vb. Identify resistance mechanisms using genomic DNA- and RNA-based assessment platforms; (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) VI. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) VII. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the National Cancer Institute (NCI) Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) at Nationwide Children's Hospital. (Phase 1, non-thoracic, non-BRD4 exploratory cohort, and ZEN003694/carboplatin/paclitaxel safety cohort) VIII. Evaluate the safety and tolerability of ZEN003694 in combination with carboplatin and paclitaxel in participants with NC. (ZEN003694/carboplatin/paclitaxel safety cohort) IX. To determine the PK profile of the combination of ZEN003694, carboplatin, and paclitaxel in combination. (ZEN003694/carboplatin/paclitaxel safety cohort)
OUTLINE: This is a dose escalation study of ZEN003694 with fixed dose etoposide and cisplatin OR fixed dose carboplatin and paclitaxel. Patients are assigned to 1 of 3 cohorts.
COHORT I (PHASE 1): Patients receive ZEN003694 orally (PO) once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive etoposide intravenously (IV) over 60 minutes on days 1-3 of each cycle and cisplatin IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then receive etoposide and cisplatin for an additional 4 cycles in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. After completion of etoposide and cisplatin treatment, patients may then receive ZEN003694 PO once or twice daily on days 1-14 or 1-21 of each cycle, per the treating investigator's discretion. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
COHORT II (SAFETY COHORT): Patients receive ZEN003694 PO once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive carboplatin IV over 15-30 minutes on day 1 of each cycle and paclitaxel IV over 3 hours on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then receive carboplatin and paclitaxel for an additional 4 cycles in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. After completion of carboplatin and paclitaxel treatment, patients may then receive ZEN003694 PO once or twice daily on days 1-14 or 1-21 of each cycle, per the treating investigator's discretion. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
COHORT III (NON-THORACIC, NON-BRD4 EXPLORATORY COHORT): Patients receive ZEN003694 PO on days 1-5, 8-12, and 15-19 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression have the option to cross-over to Cohort I and receive treatment for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Cross-over patients may then receive ZEN003694 PO on days 1-21 of each cycle in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
After completion of study treatment, patients are followed for 30 days after the last dose and then every 4 weeks for a maximum of 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced NUT Carcinoma
Metastatic NUT Carcinoma
Unresectable NUT Carcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort I (ZEN003694, etoposide, cisplatin)
Patients receive ZEN003694 PO once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive etoposide IV over 60 minutes on days 1-3 of each cycle and cisplatin IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then receive etoposide and cisplatin for an additional 4 cycles in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. After completion of etoposide and cisplatin treatment, patients may then receive ZEN003694 PO once or twice daily on days 1-14 or 1-21 of each cycle, per the treating investigator's discretion. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
Group Type
EXPERIMENTAL
BET Bromodomain Inhibitor ZEN-3694
Intervention Type
DRUG
Given PO
Biopsy Procedure
Intervention Type
PROCEDURE
Undergo biopsy
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Cisplatin
Intervention Type
DRUG
Given IV
Etoposide
Intervention Type
DRUG
Given IV
Imaging Procedure
Intervention Type
PROCEDURE
Undergo imaging scans
Cohort II (ZEN003694, carboplatin, paclitaxel)
Patients receive ZEN003694 PO once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive carboplatin IV over 15-30 minutes on day 1 of each cycle and paclitaxel IV over 3 hours on day 1 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then receive carboplatin and paclitaxel for an additional 4 cycles in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. After completion of carboplatin and paclitaxel treatment, patients may then receive ZEN003694 PO once or twice daily on days 1-14 or 1-21 of each cycle, per the treating investigator's discretion. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
Group Type
EXPERIMENTAL
BET Bromodomain Inhibitor ZEN-3694
Intervention Type
DRUG
Given PO
Biopsy Procedure
Intervention Type
PROCEDURE
Undergo biopsy
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Carboplatin
Intervention Type
DRUG
Given IV
Imaging Procedure
Intervention Type
PROCEDURE
Undergo imaging scans
Paclitaxel
Intervention Type
DRUG
Given IV
Cohort III (ZEN003694)
Patients receive ZEN003694 PO on days 1-5, 8-12, and 15-19 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression have the option to cross-over to Cohort I and receive treatment for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Cross-over patients may then receive ZEN003694 PO on days 1-21 of each cycle in the absence of disease progression or unacceptable toxicity, per the treating investigator's discretion. Patients also undergo imaging scans, blood sample collection, and biopsies throughout the study.
Group Type
EXPERIMENTAL
BET Bromodomain Inhibitor ZEN-3694
Intervention Type
DRUG
Given PO
Biopsy Procedure
Intervention Type
PROCEDURE
Undergo biopsy
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Imaging Procedure
Intervention Type
PROCEDURE
Undergo imaging scans
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BET Bromodomain Inhibitor ZEN-3694
Given PO
Intervention Type
DRUG
Biopsy Procedure
Undergo biopsy
Intervention Type
PROCEDURE
Biospecimen Collection
Undergo blood sample collection
Intervention Type
PROCEDURE
Carboplatin
Given IV
Intervention Type
DRUG
Cisplatin
Given IV
Intervention Type
DRUG
Etoposide
Given IV
Intervention Type
DRUG
Imaging Procedure
Undergo imaging scans
Intervention Type
PROCEDURE
Paclitaxel
Given IV
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
BETi ZEN-3694
ZEN 3694
ZEN-3694
ZEN003694
Biopsy
BIOPSY_TYPE
Bx
Biological Sample Collection
Biospecimen Collected
Specimen Collection
Blastocarb
Carboplat
Carboplatin Hexal
Carboplatino
Carboplatinum
Carbosin
Carbosol
Carbotec
CBDCA
Displata
Ercar
JM-8
JM8
Nealorin
Novoplatinum
Paraplatin
Paraplatin AQ
Paraplatine
Platinwas
Ribocarbo
Abiplatin
Blastolem
Briplatin
CDDP
Cis-diammine-dichloroplatinum
Cis-diamminedichloridoplatinum
Cis-diamminedichloro Platinum (II)
Cis-diamminedichloroplatinum
Cis-dichloroammine Platinum (II)
Cis-platinous Diamine Dichloride
Cis-platinum
Cis-platinum II
Cis-platinum II Diamine Dichloride
Cismaplat
Cisplatina
Cisplatinum
Cisplatyl
Citoplatino
Citosin
Cysplatyna
DDP
Lederplatin
Metaplatin
Neoplatin
Peyrone's Chloride
Peyrone's Salt
Placis
Plastistil
Platamine
Platiblastin
Platiblastin-S
Platinex
Platinol
Platinol- AQ
Platinol-AQ
Platinol-AQ VHA Plus
Platinoxan
Platinum
Platinum Diamminodichloride
Platiran
Platistin
Platosin
Demethyl Epipodophyllotoxin Ethylidine Glucoside
EPEG
Lastet
Toposar
Vepesid
VP 16
VP 16-213
VP 16213
VP-16
VP-16-213
VP-16213
VP16
VP16213
Diagnostic Imaging Technique
Image Type
Imaging
Imaging (procedure)
Imaging Procedures
Imaging Technique
imaging type
IMAGING_METHOD
imaging_type
Medical Imaging
Type of imaging
Anzatax
Asotax
Bristaxol
Praxel
Taxol
Taxol Konzentrat
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants must have a diagnosis of NC based on standard criteria for the disease, with diagnostic testing performed in a Clinical Laboratory Improvement Act (CLIA) certified laboratory:
* Ectopic expression of NUT protein per World Health Organization (WHO) criteria (World Health Organization \[WHO\], 2021) as determined by immunohistochemistry (IHC) testing, OR
* Detection of the NUT gene translocation as determined by fluorescence in situ hybridization (FISH) testing, OR
* Detection of the NUT gene translocation as determined by sequencing, eg. DNA next generation sequencing (NGS) or RNA sequencing.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants must have disease that is metastatic, unresectable, or for which a surgical approach would not likely confer a survival benefit or would be otherwise contraindicated. Participants who have already undergone surgical resection are eligible to participate in Phase 1.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Age \>= 12 years. Patients 12-17 years of age must be \>= 40 kg at enrollment. Because no dosing or adverse event data are currently available on the use of ZEN003694 in combination with etoposide and cisplatin in patients \< 12 years of age, younger children are excluded from this study.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 (Karnofsky \>= 60%) for patients \>= 16 years of age, Lansky \>= 50% if \< 16 years of age.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants must have measurable disease per RECIST version 1.1 criteria. Patients in the phase 1 portion do not need measurable disease if their disease is otherwise evaluable.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Ability to swallow and retain oral medications.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Absolute neutrophil count \>= 1.5 x 10\^9/L.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Platelets \>= 125 x 10\^9/L.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Hemoglobin \>= 9.0 g/dL.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Albumin \>= 2.5 g/dL.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) for age.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase(ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN for age.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Calculated creatinine clearance \>= 60 mL/min (based on the calculated Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] glomerular filtration rate estimation for adults or 60 mL/min/1.73m\^2 for patients 12-17 years as calculated based on bedside Schwartz formula).
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Prothrombin time (PT)/international normalized ratio (INR) =\< 1.5 x ULN.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Partial thromboplastin time (PTT) =\< 1.5 x ULN.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: QT interval by Fridericia (QTcF) \< 450 ms (machine or manual read allowed). Patients should avoid medications which prolong the QT.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 3 months are eligible for this trial as long as their anti-retroviral therapy does not have the potential for drug-drug interactions as judged by the treating investigator.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Hepatitis C (HepC antibody) testing is required. Hepatitis C RNA is optional; however, a confirmatory negative hepatitis C RNA test must be obtained to be able to enroll participants with positive hepatitis C antibody due to prior resolved disease.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for treatment in the phase 1 portion, but not in the non-thoracic, non-BRD4 exploratory cohort. Participants enrolling to the non-thoracic, non-BRD4 exploratory cohort with a history of prior malignancy are eligible only if they fit one or more of the following criteria: participants with non-melanoma skin cancers that have been curatively treated; participants with adequately treated carcinomas in situ of any type; or participants who were diagnosed and curatively treated at least 3 years prior to the date of study entry and who are considered by the treating investigator to be at low risk for recurrence.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: The effects of ZEN003694 on the developing human fetus are unknown. For this reason and because the chemotherapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 4 months after completion of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study therapy. For female subjects of child-bearing potentially receiving ZEN003694, hormonal means of birth control alone, such as oral, injectable, dermal, subdermal or topical contraceptives are NOT acceptable forms of birth control given that their efficacy has not been evaluated when given in combination with the investigational drugs. "Adequate contraception" is defined as the following: Contraceptive methods with a failure rate of =\< 1% used in combination with the barrier method. The following contraceptive methods are acceptable to use in combination with the barrier method: intrauterine device (IUD), intrauterine system (IUS), or oral contraceptive pills (OCPs) that meet the \< 1% failure rate as stated in the product label. Note: Hormonal IUDs/OCPs may only be used if the following criteria are met: male condoms are required AND subjects are informed of the potential for reduced systemic hormone levels from the IUD/OCP when taking ZEN003694. Alternatively, male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records. Male subjects with female partners of child-bearing potential must use one of the following contraceptive methods:
* Vasectomy with documentation of azoospermia OR
* Condom use PLUS partner use of a highly effective contraceptive (=\< 1% rate of failure per year) such as intrauterine device or system, or hormonal birth control such as contraceptive subdermal implant, combined estrogen and progestogen oral contraceptive, injectable progestogen, contraceptive vaginal ring, or percutaneous contraceptive patches.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Male subjects should not donate sperm while on study and for 16 weeks after the last dose of study medication. Male subjects whose partners are or become pregnant must continue to use condoms for 16 weeks after the last dose of study medication.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Ability to understand and the willingness to sign a written informed consent document (or parent or legally authorized representative if minor). Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available may be eligible after discussion with the Principal Investigator of this study.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Women of childbearing potential must have a negative pregnancy test within 7 days of starting treatment.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants who have not had cytotoxic chemotherapy, oral tyrosine kinase inhibitor (TKI) or small molecule therapy, or immunotherapy within 2 weeks prior to the first dose of study medication or 5 half-lives, whichever is shorter. For the phase 1 dose escalation, there is no required washout for previous EP therapy. For the carboplatin/paclitaxel safety cohort, there is no required washout for prior carboplatin/paclitaxel therapy
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants may have had a maximum of 1 prior cycle of EP (cisplatin + etoposide) or carboplatin/paclitaxel. However, for consistency, cycle 1 day 1 will be the first day of EP or carboplatin/paclitaxel on the Phase 1 portions of the study. There is no required washout for previous ZEN003694 therapy for patients enrolling to the phase 1 portion of the study
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants who have received prior radiation therapy can be enrolled at least 1 week after completing radiation.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants who have had major surgery can be enrolled at least 3 weeks after the surgery.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Any therapy-related toxicities must have resolved to ≤ grade 1 or baseline (with the exception of alopecia, peripheral neuropathy, or rash that will be permitted at ≤ grade 2). Other grade 2 toxicities attributed to prior treatment may be permitted with agreement from the overall principal investigator if they are toxicities not commonly attributed to ZEN003694. Toxicities attributed to current EP or carboplatin/paclitaxel therapy are excluded from this requirement for participants enrolling to the dose escalation or carboplatin/paclitaxel safety cohort, as long as the participant meets all other eligibility criteria.
* NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants must have a diagnosis of NC but lack BRD4-NUT rearrangement. If the fusion status is unknown after NC diagnosis, the BRD4-NUT fusion status will be determined by centralized FISH testing at the BWH Center for Advanced Molecular Diagnostics (CAMD).
* Ectopic expression of NUT protein per World Health Organization (WHO) criteria (World Health Organization \[WHO\], 2021) as determined by immunohistochemistry (IHC) testing, OR
* Detection of the NUT gene translocation as determined by fluorescence in situ hybridization (FISH) testing, OR
* Detection of the NUT gene translocation as determined by sequencing, eg. DNA next generation sequencing (NGS) or RNA sequencing.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants must have disease that is metastatic, unresectable, or for which a surgical approach would not likely confer a survival benefit or would be otherwise contraindicated. Participants who have already undergone surgical resection are eligible to participate in Phase 1.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Age \>= 12 years. Patients 12-17 years of age must be \>= 40 kg at enrollment. Because no dosing or adverse event data are currently available on the use of ZEN003694 in combination with etoposide and cisplatin in patients \< 12 years of age, younger children are excluded from this study.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 (Karnofsky \>= 60%) for patients \>= 16 years of age, Lansky \>= 50% if \< 16 years of age.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants must have measurable disease per RECIST version 1.1 criteria. Patients in the phase 1 portion do not need measurable disease if their disease is otherwise evaluable.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Ability to swallow and retain oral medications.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Absolute neutrophil count \>= 1.5 x 10\^9/L.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Platelets \>= 125 x 10\^9/L.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Hemoglobin \>= 9.0 g/dL.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Albumin \>= 2.5 g/dL.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) for age.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase(ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN for age.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Calculated creatinine clearance \>= 60 mL/min (based on the calculated Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] glomerular filtration rate estimation for adults or 60 mL/min/1.73m\^2 for patients 12-17 years as calculated based on bedside Schwartz formula).
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Prothrombin time (PT)/international normalized ratio (INR) =\< 1.5 x ULN.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Partial thromboplastin time (PTT) =\< 1.5 x ULN.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: QT interval by Fridericia (QTcF) \< 450 ms (machine or manual read allowed). Patients should avoid medications which prolong the QT.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 3 months are eligible for this trial as long as their anti-retroviral therapy does not have the potential for drug-drug interactions as judged by the treating investigator.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Hepatitis C (HepC antibody) testing is required. Hepatitis C RNA is optional; however, a confirmatory negative hepatitis C RNA test must be obtained to be able to enroll participants with positive hepatitis C antibody due to prior resolved disease.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for treatment in the phase 1 portion, but not in the non-thoracic, non-BRD4 exploratory cohort. Participants enrolling to the non-thoracic, non-BRD4 exploratory cohort with a history of prior malignancy are eligible only if they fit one or more of the following criteria: participants with non-melanoma skin cancers that have been curatively treated; participants with adequately treated carcinomas in situ of any type; or participants who were diagnosed and curatively treated at least 3 years prior to the date of study entry and who are considered by the treating investigator to be at low risk for recurrence.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: The effects of ZEN003694 on the developing human fetus are unknown. For this reason and because the chemotherapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 4 months after completion of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study therapy. For female subjects of child-bearing potentially receiving ZEN003694, hormonal means of birth control alone, such as oral, injectable, dermal, subdermal or topical contraceptives are NOT acceptable forms of birth control given that their efficacy has not been evaluated when given in combination with the investigational drugs. "Adequate contraception" is defined as the following: Contraceptive methods with a failure rate of =\< 1% used in combination with the barrier method. The following contraceptive methods are acceptable to use in combination with the barrier method: intrauterine device (IUD), intrauterine system (IUS), or oral contraceptive pills (OCPs) that meet the \< 1% failure rate as stated in the product label. Note: Hormonal IUDs/OCPs may only be used if the following criteria are met: male condoms are required AND subjects are informed of the potential for reduced systemic hormone levels from the IUD/OCP when taking ZEN003694. Alternatively, male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records. Male subjects with female partners of child-bearing potential must use one of the following contraceptive methods:
* Vasectomy with documentation of azoospermia OR
* Condom use PLUS partner use of a highly effective contraceptive (=\< 1% rate of failure per year) such as intrauterine device or system, or hormonal birth control such as contraceptive subdermal implant, combined estrogen and progestogen oral contraceptive, injectable progestogen, contraceptive vaginal ring, or percutaneous contraceptive patches.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Male subjects should not donate sperm while on study and for 16 weeks after the last dose of study medication. Male subjects whose partners are or become pregnant must continue to use condoms for 16 weeks after the last dose of study medication.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Ability to understand and the willingness to sign a written informed consent document (or parent or legally authorized representative if minor). Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available may be eligible after discussion with the Principal Investigator of this study.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Women of childbearing potential must have a negative pregnancy test within 7 days of starting treatment.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants who have not had cytotoxic chemotherapy, oral tyrosine kinase inhibitor (TKI) or small molecule therapy, or immunotherapy within 2 weeks prior to the first dose of study medication or 5 half-lives, whichever is shorter. For the phase 1 dose escalation, there is no required washout for previous EP therapy. For the carboplatin/paclitaxel safety cohort, there is no required washout for prior carboplatin/paclitaxel therapy
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants may have had a maximum of 1 prior cycle of EP (cisplatin + etoposide) or carboplatin/paclitaxel. However, for consistency, cycle 1 day 1 will be the first day of EP or carboplatin/paclitaxel on the Phase 1 portions of the study. There is no required washout for previous ZEN003694 therapy for patients enrolling to the phase 1 portion of the study
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants who have received prior radiation therapy can be enrolled at least 1 week after completing radiation.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants who have had major surgery can be enrolled at least 3 weeks after the surgery.
* PHASE 1, CARBOPLATIN/PACLITAXEL SAFETY COHORT, \& NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Any therapy-related toxicities must have resolved to ≤ grade 1 or baseline (with the exception of alopecia, peripheral neuropathy, or rash that will be permitted at ≤ grade 2). Other grade 2 toxicities attributed to prior treatment may be permitted with agreement from the overall principal investigator if they are toxicities not commonly attributed to ZEN003694. Toxicities attributed to current EP or carboplatin/paclitaxel therapy are excluded from this requirement for participants enrolling to the dose escalation or carboplatin/paclitaxel safety cohort, as long as the participant meets all other eligibility criteria.
* NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Participants must have a diagnosis of NC but lack BRD4-NUT rearrangement. If the fusion status is unknown after NC diagnosis, the BRD4-NUT fusion status will be determined by centralized FISH testing at the BWH Center for Advanced Molecular Diagnostics (CAMD).
Exclusion Criteria
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Participants with known untreated central nervous system (CNS) metastases. Patients with a history of treated CNS metastases are eligible, provided they meet the following criteria:
* Radiologically stable for 4 weeks.
* Disease outside the CNS is present.
* Recovery from acute toxicity associated with the treatment to =\< Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or baseline (with the exception of alopecia), with no requirement for escalating doses of corticosteroids over the past 7 days.
* Subjects currently taking enzyme-inducing anticonvulsants (EIAC) must be transitioned to non-enzyme inducing anticonvulsants at least 14 days or 5 half-lives prior to the first dose of study medication
* No presence of symptomatic or untreated leptomeningeal metastases or spinal cord compression.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 or other agents used in study.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring systemic treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patients with myocardial infarction or unstable angina within 6 months prior to the first dose of ZEN003694 will be excluded.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Any gastrointestinal (GI) disorder that may affect absorption of ZEN003694 and other oral medications in the opinion of the treating investigator, such as malabsorption syndrome or major bowel or stomach resection.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients who are receiving any other investigational agents.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or substrates of CYP1A2 with narrow therapeutic windows are ineligible. Strong inhibitors or inducers of CYP3A4 must be discontinued at least 7 days prior to the first dose of ZEN003694. As proton pump inhibitors (PPIs), H2 receptor antagonists, and antacids may alter the pharmacokinetics of ZEN003694 by reducing ZEN003694 exposure, patients receiving proton pump inhibitors are ineligible. If H2 blockers or other acid reducing agents are used concomitantly with ZEN003694, a staggered dosing schedule should be used, either dose ZEN-3694 2 hours before the H2 blocker or 10-12 hours after an H2 blocker. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Pregnant women are excluded from this study because ZEN003694 is a bromodomain and extraterminal domain (BET) inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694, breastfeeding should be discontinued if the mother is treated with ZEN003694. These potential risks may also apply to other agents used in this study.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients receiving therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin \[LMWH\], or novel oral anticoagulants) are not eligible. Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran) is not permitted. Prophylactic anticoagulation, with low doses (per standard practice) of agents such as low molecular weight heparin (LMWH) is permitted.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients with radiation to \> 25% of the bone marrow.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Cardiac abnormalities as evidenced by any of the following:
* Clinically significant conduction abnormalities or arrhythmias.
* History or evidence of current \>= class II congestive heart failure as defined by New York Heart Association (NYHA).
* History of acute coronary syndromes (including unstable angina and myocardial infarction), coronary angioplasty, or stenting within the past 3 months. Subjects with a history of stent placement requiring ongoing antithrombotic therapy (e.g., clopidogrel, prasugrel) will not be permitted to enroll.
* Clinically significant cardiomegaly, ventricular hypertrophy, or cardiomyopathy.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients with uncontrolled intercurrent illness.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients with psychiatric illness/social situations that would limit compliance with study requirements.
* PHASE 1: Patients who are currently receiving EP or ZEN003694, or received EP or ZEN003694 in the past, must be candidates to receive the study agents at the protocol-defined dose level and schedule as judged by the treating investigator. Patients who previously required dose reductions of their EP or ZEN003694 due to unacceptable toxicities attributed to the agent(s) are not eligible.
* ZEN003694/CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients who are currently receiving carboplatin/paclitaxel or ZEN003694, or received carboplatin/paclitaxel or ZEN003694 in the past, must be candidates to receive the study agents at the protocol-defined dose level and schedule as judged by the treating investigator. Patients who previously required dose reductions of their carboplatin/paclitaxel or ZEN003694 due to unacceptable toxicities attributed to the agent(s) are not eligible.
* PHASE 1 OR ZEN003694/CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients ineligible for receiving EP or carboplatin/paclitaxel for either the phase 1 dose escalation or the carboplatin/paclitaxel safety cohort, respectively.
* NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients with disease that definitively originated in the thoracic cavity. In the case of patients with metastatic disease at diagnosis where disease origin is uncertain, the patient may be allowed to enroll.
* NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients who previously received treatment with a BET inhibitor (BETi), including but not limited to previous ZEN003694 therapy.
* Radiologically stable for 4 weeks.
* Disease outside the CNS is present.
* Recovery from acute toxicity associated with the treatment to =\< Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or baseline (with the exception of alopecia), with no requirement for escalating doses of corticosteroids over the past 7 days.
* Subjects currently taking enzyme-inducing anticonvulsants (EIAC) must be transitioned to non-enzyme inducing anticonvulsants at least 14 days or 5 half-lives prior to the first dose of study medication
* No presence of symptomatic or untreated leptomeningeal metastases or spinal cord compression.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 or other agents used in study.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring systemic treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patients with myocardial infarction or unstable angina within 6 months prior to the first dose of ZEN003694 will be excluded.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Any gastrointestinal (GI) disorder that may affect absorption of ZEN003694 and other oral medications in the opinion of the treating investigator, such as malabsorption syndrome or major bowel or stomach resection.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients who are receiving any other investigational agents.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or substrates of CYP1A2 with narrow therapeutic windows are ineligible. Strong inhibitors or inducers of CYP3A4 must be discontinued at least 7 days prior to the first dose of ZEN003694. As proton pump inhibitors (PPIs), H2 receptor antagonists, and antacids may alter the pharmacokinetics of ZEN003694 by reducing ZEN003694 exposure, patients receiving proton pump inhibitors are ineligible. If H2 blockers or other acid reducing agents are used concomitantly with ZEN003694, a staggered dosing schedule should be used, either dose ZEN-3694 2 hours before the H2 blocker or 10-12 hours after an H2 blocker. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Pregnant women are excluded from this study because ZEN003694 is a bromodomain and extraterminal domain (BET) inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694, breastfeeding should be discontinued if the mother is treated with ZEN003694. These potential risks may also apply to other agents used in this study.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients receiving therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin \[LMWH\], or novel oral anticoagulants) are not eligible. Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran) is not permitted. Prophylactic anticoagulation, with low doses (per standard practice) of agents such as low molecular weight heparin (LMWH) is permitted.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients with radiation to \> 25% of the bone marrow.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Cardiac abnormalities as evidenced by any of the following:
* Clinically significant conduction abnormalities or arrhythmias.
* History or evidence of current \>= class II congestive heart failure as defined by New York Heart Association (NYHA).
* History of acute coronary syndromes (including unstable angina and myocardial infarction), coronary angioplasty, or stenting within the past 3 months. Subjects with a history of stent placement requiring ongoing antithrombotic therapy (e.g., clopidogrel, prasugrel) will not be permitted to enroll.
* Clinically significant cardiomegaly, ventricular hypertrophy, or cardiomyopathy.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients with uncontrolled intercurrent illness.
* PHASE 1, NON-THORACIC, NON-BRD4 EXPLORATORY COHORT, \& CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients with psychiatric illness/social situations that would limit compliance with study requirements.
* PHASE 1: Patients who are currently receiving EP or ZEN003694, or received EP or ZEN003694 in the past, must be candidates to receive the study agents at the protocol-defined dose level and schedule as judged by the treating investigator. Patients who previously required dose reductions of their EP or ZEN003694 due to unacceptable toxicities attributed to the agent(s) are not eligible.
* ZEN003694/CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients who are currently receiving carboplatin/paclitaxel or ZEN003694, or received carboplatin/paclitaxel or ZEN003694 in the past, must be candidates to receive the study agents at the protocol-defined dose level and schedule as judged by the treating investigator. Patients who previously required dose reductions of their carboplatin/paclitaxel or ZEN003694 due to unacceptable toxicities attributed to the agent(s) are not eligible.
* PHASE 1 OR ZEN003694/CARBOPLATIN/PACLITAXEL SAFETY COHORT: Patients ineligible for receiving EP or carboplatin/paclitaxel for either the phase 1 dose escalation or the carboplatin/paclitaxel safety cohort, respectively.
* NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients with disease that definitively originated in the thoracic cavity. In the case of patients with metastatic disease at diagnosis where disease origin is uncertain, the patient may be allowed to enroll.
* NON-THORACIC, NON-BRD4 EXPLORATORY COHORT: Patients who previously received treatment with a BET inhibitor (BETi), including but not limited to previous ZEN003694 therapy.
Minimum Eligible Age
12 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jia Luo
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber - Harvard Cancer Center LAO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles General Medical Center
Los Angeles, California, United States
Site Status
RECRUITING
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Site Status
RECRUITING
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site Status
RECRUITING
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States
Site Status
RECRUITING
M D Anderson Cancer Center
Houston, Texas, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site Public Contact
Role: primary
Site Public Contact
Role: primary
Site Public Contact
Role: primary
Site Public Contact
Role: primary
Site Public Contact
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Roden AC. Molecularly Defined Thoracic Neoplasms. Adv Anat Pathol. 2024 Sep 1;31(5):303-317. doi: 10.1097/PAP.0000000000000439. Epub 2024 Mar 19.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-08926
Identifier Type: REGISTRY
Identifier Source: secondary_id
10507
Identifier Type: OTHER
Identifier Source: secondary_id
10507
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2021-08926
Identifier Type: -
Identifier Source: org_study_id